Marathon Asset Management Ltd Cuts Stock Position in Henry Schein, Inc. $HSIC

Marathon Asset Management Ltd lessened its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 26.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 171,888 shares of the company’s stock after selling 61,529 shares during the quarter. Marathon Asset Management Ltd owned 0.14% of Henry Schein worth $11,408,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Ameriprise Financial Inc. grew its stake in shares of Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after acquiring an additional 2,199,695 shares in the last quarter. Norges Bank purchased a new position in Henry Schein in the second quarter valued at about $89,476,000. M.D. Sass LLC acquired a new stake in Henry Schein during the 2nd quarter valued at approximately $79,201,000. Schroder Investment Management Group grew its stake in Henry Schein by 149.3% during the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock valued at $114,243,000 after purchasing an additional 936,471 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in Henry Schein by 204.2% during the 2nd quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after purchasing an additional 668,182 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Trading Down 0.1%

Shares of HSIC stock opened at $76.13 on Monday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $82.49. The stock has a fifty day moving average of $71.79 and a two-hundred day moving average of $69.96. The firm has a market capitalization of $8.96 billion, a PE ratio of 24.09, a price-to-earnings-growth ratio of 2.33 and a beta of 0.89.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. The company had revenue of $3.34 billion for the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. As a group, research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on HSIC shares. Wells Fargo & Company boosted their target price on shares of Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 22nd. JPMorgan Chase & Co. upped their price objective on Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Evercore ISI lifted their target price on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Finally, Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $76.92.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.